Clinical Trial Update: 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial updates show 24-week efficacy and 3-year safety and efficacy data for secukinumab in active psoriatic arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriatic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2019-04-16